[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:acute-leukemia-of-ambiguous-lineage:npm1-gene":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Acute Leukemia of Ambiguous Lineage","NPM1 Gene",4,[8,16,22,29],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06177067","Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia",[12],"Phase 1","RECRUITING","2026-08-26T02:19:29.119921Z","2026-05-05T02:43:27.978998Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT06575296","Revumenib for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell Transplant",[12],"2026-08-26T02:18:40.612983Z","2026-05-05T02:43:27.843378Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":27,"content_modified":28},"NCT04065399","A Study of Revumenib in R\u002FR Leukemias Including Those With an MLL\u002FKMT2A Gene Rearrangement or NPM1 Mutation",[26],"Phase 1\u002FPhase 2","2026-08-26T02:18:48.678868Z","2026-05-05T02:43:27.111185Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT06397027","A Phase I Study Investigating the Combination of the Ziftomenib, Venetoclax and Azacitidine in Pediatric Relapsed and Refractory Acute Leukemias",[12],"2026-08-26T02:16:17.877565Z","2026-05-05T02:43:27.100920Z"]